comprehensive -WSS

comprehensive

author：hotspot 2025-10-01 21:40:34 - browse：7

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： 6 solutions to address cancer drug shortages and others

WSS

IVG is promising — but it won’t replace IVF quite yet

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Overprescribed: High cost isn't America's only drug problem

Health insurers' Q3 question: how much care are people getting?

Lawsuit highlights wrinkle for disputes over surprise medical bills

What we owe ALS patients — and why one company fell short

knowledge

comprehensive

focus

After affirmative action ruling, medical educators look to 'holistic review'

Stop Congress from blocking public access to science

Novavax promises a turnaround & Lilly roils the obesity market

Congress extends some pandemic preparedness programs

The high cost of giving birth even with insurance

Stop Congress from blocking public access to science

The high cost of giving birth even with insurance

The biotech scorecard for Q4: 16 stock

DIEP, the 'gold standard' of breast reconstruction, is under threat

Gut bacteria may contribute to kidney autoimmunity, study finds

explore

Some top drug companies are starting to take action on climate

Setback for rare diseases as Taysha Gene Therapies pulls back

With Roe v Wade overturned, abortion providers work to adapt

U.K. decision on ALS drug has neurologists, advocates up in arms

Flu, Covid vaccination rates decline, new survey data show

IVG is promising — but it won’t replace IVF quite yet

focus

focus

focus

hotspot